Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 1.00 |
| ▸ | IP6K1 | Q92551 | 8/20 | 0.69 |
| ▸ | IP6K3 | Q96PC2 | 5/20 | 0.69 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.64 |
| ▸ | PIM1 | P11309 | 1/20 | 0.64 |
| ▸ | AKT1 | P31749 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.64 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.56 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2191067 | 1.00 | PARP1 (1.00) | PARP1IP6K1IP6K3CHEK1PIM1 | |
| Hydrochloric Acid SCHEMBL30141968 | 0.98 | PARP1 (0.96) | PARP1IP6K1IP6K3CHEK1PIM1 | |
| SCHEMBL29967106 | 0.85 | PARP1 (0.74) | PARP1IP6K1IP6K3CHEK1PIM1 | |
| SCHEMBL24819 | 0.85 | PARP1 (0.74) | PARP1IP6K1IP6K3CHEK1PIM1 | |
| Ethoxycarbonyl Group SCHEMBL27845957 | 0.83 | PARP1 (0.69) | PARP1IP6K1IP6K3CHEK1PIM1 | |
| SCHEMBL8622180 | 0.81 | ACVR1 (0.73) | PARP1IP6K1IP6K3CHEK1PIM1 | |
| SCHEMBL9263181 | 0.78 | PARP1 (0.64) | PARP1IP6K1IP6K3CHEK1PIM1 | |
| SCHEMBL2081677 | 0.78 | PARP1 (1.00) | PARP1IP6K1IP6K3CHEK1PIM1 | |
| SCHEMBL216176 | 0.78 | PARP1 (1.00) | PARP1IP6K1IP6K3CHEK1PIM1 | |
| SCHEMBL642178 | 0.78 | PARP1 (1.00) | PARP1IP6K1IP6K3CHEK1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118996447-A | Phosphine-oxide substituted quinoxaline quinazolinone compound, preparation method and application thereof | 南阳师范学院 | 2024-11-22 | — | — | CN | claimed |
| EP-4313295-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2024-02-07 | — | — | EP | claimed |
| WO-2022200523-A1 | PHARMACEUTICALS COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2022-09-29 | — | — | WO | claimed |
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | claimed |
| CN-119462526-A | Method for synthesizing quinazolinone compound by catalytic cyclization of titanocene dichloride | 陕西师范大学 | 2025-02-18 | — | — | CN | disclosed |
| CN-118996447-A | Phosphine-oxide substituted quinoxaline quinazolinone compound, preparation method and application thereof | 南阳师范学院 | 2024-11-22 | — | — | CN | disclosed |
| US-20240327382-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 | ALMAC DISCOVERY LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| CN-118591537-A | PARP7 inhibitors | 吉利德科学公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-117946012-A | Preparation method of nitrogen-containing heterocycle | 温州理工学院 | 2024-04-30 | — | — | CN | disclosed |
| CN-115260164-B | Preparation method, structural composition and application of novel 4 (3H) -quinazolinone analogue in antitumor drugs | 杭州星鳌生物科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4313295-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157285-A | Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors | 阿尔麦克探索有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-113637011-B | Myricetin derivative containing quinazoline-4 (3H) -ketone and preparation method and application thereof | 贵州大学 | 2023-03-31 | — | — | CN | disclosed |
| WO-2022200523-A9 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022233253-A1 | METHOD FOR PREPARING NEW 4(3H)-QUINAZOLINONE ANALOG, STRUCTURAL COMPOSITION THEREOF, AND USE THEREOF IN ANTITUMOR DRUGS | 杭州星鳌生物科技有限公司 | 2022-11-10 | — | — | WO | disclosed |
| CN-115260164-A | Preparation method and structural composition of novel 4 (3H) -quinazolinone analogue and application of analogue in antitumor drugs | 杭州星鳌生物科技有限公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2022200523-A1 | PHARMACEUTICALS COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327382-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 | USP19, USP18, UBE2I | PARP1 1106/4885IP6K1 3487/4885IP6K3 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.